1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Prostatic Neoplasms, Castration-Resistant in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 4 (80.00) | 2.80 |
Authors | Studies |
---|---|
Keam, SJ | 1 |
Jacene, H; Ravi, P; Shah, H; Sonpavde, G | 1 |
Agrawal, S; Amiri-Kordestani, L; Chen, W; Chiang, K; Fallah, J; Fiero, MH; Fotenos, A; Gittleman, H; Ibrahim, A; John, C; Kluetz, PG; Niu, G; Pazdur, R; Pierce, WF; Ricks, TK; Subramaniam, S; Suzman, DL; Tang, S; Wang, M | 1 |
Chen, ZS; Fang, GC; Han, CH; Liu, X; Lu, H; Shi, ZD | 1 |
Bander, NH; Goldsmith, SJ; Jhanwar, YS; Kaur, G; Nanus, DM; Nikolopoulou, A; Tagawa, ST; Vallabhajosula, S | 1 |
4 review(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Prostatic Neoplasms, Castration-Resistant
Article | Year |
---|---|
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
Topics: Antineoplastic Agents; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2022 |
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
Topics: Clinical Trials, Phase II as Topic; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2022 |
Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
Topics: Animals; Antibodies, Monoclonal; Antigens, Surface; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Male; Maximum Tolerated Dose; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Xenograft Model Antitumor Assays | 2016 |
1 trial(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Prostatic Neoplasms, Castration-Resistant
Article | Year |
---|---|
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Topics: Adult; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Receptors, Androgen; Taxoids; Treatment Outcome | 2023 |